

## Component 2: The Culture of Health Care

### Unit 7: Quality Measurement, Performance Improvement, and Incentive Payment Schemes Lecture 4

This material was developed by Oregon Health & Science University, funded by the Department of Health and Human  
Services, Office of the National Coordinator for Health Information Technology under Award Number H240C000015.

---

---

---

---

---

---

---

---

## Overview

- State of the quality of care
- Definitions and operationalization of quality measurement and improvement
- Quality measures
- Role of information technology (IT) and informatics
- Results of current approaches
- Challenges, limitations, and ethical issues
- Quality measurement and improvement under meaningful use

Component 2/Unit 7-4

Health IT Workforce Curriculum  
Version 2.0/Spring 2011

2

---

---

---

---

---

---

---

---

## Clinical quality measures and meaningful use

- One of the five healthcare goals for meaningful use is: Improving quality, safety, and efficiency
- One of the 15 core measures for eligible professionals (EPs) is reporting of clinical quality measures to CMS or the states
- One of the 14 core measures for eligible hospitals (EHs) is reporting of clinical quality measures to CMS or the states

Component 2/Unit 7-4

Health IT Workforce Curriculum  
Version 2.0/Spring 2011

3

---

---

---

---

---

---

---

---

### Specific clinical quality measures in meaningful use rules

- EPs must report on
  - 3 core measures
    - Can substitute alternate core measures if denominator of any core measure is 0
  - 3 of 38 additional measures
- EHs must report on 15 measures
- Reporting by attestation in 2011 and provision of data in 2012 and beyond
- CMS aims to align all quality reporting programs, i.e., PQRI, CHIPRA, RHQDAPU, etc.

---

---

---

---

---

---

---

---

---

---

---

---

### Core EP quality measures

NQF Measure Number & PQRI Implementation Number	Clinical Quality Measure Title
NQF 0013	Hypertension: Blood Pressure Measurement
NQF 0028	Preventive Care and Screening Measure Pair: a) Tobacco Use Assessment, b) Tobacco Cessation Intervention
NQF 0421 PQRI 128	Adult Weight Screening and Follow-up

---

---

---

---

---

---

---

---

---

---

---

---

### Alternate core EP quality measures

NQF Measure Number & PQRI Implementation Number	Clinical Quality Measure Title
NQF 0024	Weight Assessment and Counseling for Children and Adolescents
NQF0041 PQRI 110	Preventive Care and Screening: Influenza Immunization for Patients 50 Years Old or Older
NQF 0038	Childhood Immunization Status

---

---

---

---

---

---

---

---

---

---

---

---

## EP additional quality measures (1-12)

- Anti-depressant medication management: (a) Effective Acute Phase Treatment, (b) Effective Continuation Phase Treatment
- Appropriate Testing for Children with Pharyngitis
- Asthma Assessment
- Asthma Pharmacologic Therapy
- Breast Cancer Screening
- Cervical Cancer Screening
- Chlamydia Screening for Women
- Colorectal Cancer Screening
- Controlling High Blood Pressure
- Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI)
- Coronary Artery Disease (CAD): Drug Therapy for Lowering LDL-Cholesterol
- Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD

Component 2/Unit 7-4

Health IT Workforce Curriculum  
Version 2.0/Spring 2011

7

---

---

---

---

---

---

---

---

---

---

## EP additional quality measures (13-24)

- Diabetes: Blood Pressure Management
- Diabetes: Eye Exam
- Diabetes: Foot Exam
- Diabetes: Hemoglobin A1c Control (<8.0%)
- Diabetes: Hemoglobin A1c Poor Control
- Diabetes: Low Density Lipoprotein (LDL) Management and Control
- Diabetes: Urine Screening
- Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care
- Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
- Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
- Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
- Heart Failure (HF): Warfarin Therapy Patients with Atrial Fibrillation

Component 2/Unit 7-4

Health IT Workforce Curriculum  
Version 2.0/Spring 2011

8

---

---

---

---

---

---

---

---

---

---

## EP additional quality measures (25-38)

- Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: a) Initiation, b) Engagement
- Ischemic Vascular Disease (IVD): Blood Pressure Management
- Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control
- Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic
- Low Back Pain: Use of Imaging Studies
- Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer
- Oncology Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients
- Pneumonia Vaccination Status for Older Adults
- Prenatal Care: Anti-D Immune Globulin
- Prenatal Care: Screening for Human Immunodeficiency Virus (HIV)
- Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
- Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients
- Smoking and Tobacco Use Cessation, Medical Assistance: a) Advising Smokers and Tobacco Users to Quit, b) Discussing Smoking and Tobacco Use Cessation Medications, c) Discussing Smoking and Tobacco Use Cessation Strategies
- Use of Appropriate Medications for Asthma

Component 2/Unit 7-4

Health IT Workforce Curriculum  
Version 2.0/Spring 2011

9

---

---

---

---

---

---

---

---

---

---

## EH quality measures

- Anticoagulation overlap therapy
- Emergency Department Throughput – admitted patients – Admission decision time to ED departure time for admitted patients
- Emergency Department Throughput – admitted patients – Median time from ED arrival to ED departure for admitted patients
- Incidence of potentially preventable venous thromboembolism
- Intensive Care Unit venous thromboembolism prophylaxis
- Ischemic or hemorrhagic stroke – Antithrombotic therapy by day 2
- Ischemic or hemorrhagic stroke – Rehabilitation assessment
- Ischemic or hemorrhagic stroke – Stroke education
- Ischemic stroke – Anticoagulation for atrial fibrillation/flutter
- Ischemic stroke – Discharge on anti-thrombotics
- Ischemic stroke – Discharge on statins
- Ischemic stroke – Thrombolytic therapy for patients arriving within 2 hours of symptom onset
- Platelet monitoring on unfractionated heparin
- Venous thromboembolism discharge instructions
- Venous thromboembolism prophylaxis within 24 hours of arrival

Component 2/Unit 7-4

Health IT Workforce Curriculum  
Version 2.0/Spring 2011

10

---

---

---

---

---

---

---

---

---

---